Name	Toshikazu Ushijima
Affiliation	Hoshi University
Country	Japan
Major Field	Cancer epigenetics

Educational Background	
1980-1982	School of Liberal Arts, Tokyo University
1982-1986	Medical School, Tokyo University
1997	Doctor of Medicine, Tokyo University

Professional Experience	
1986-1988	Physician in training, Tokyo University Hospital
1988-1989	Hematologist, Kanto-teishin Hospital
1989-1991	Research Resident at National Cancer Center Research Institute (NCCRI)
1991-1994	Research Staff, Carcinogenesis Division, NCCRI
1994-1995	Post-doctoral fellow, Center for Cancer Research, MIT
1994-1999	Section Head, Carcinogenesis Division, NCCRI
1999-2022	Chief, Carcinogenesis Division (Division of Epigenomics in 2010), NCCRI
2011-2014	Senior Deputy Director, NCCRI
2020-2022	Deputy Director, Japan Health Research Promotion Bureau (JH)
2022-	President, Hoshi University

Main Scientific Publications

1. Takeuchi C, Yamashita S, Liu YY, Takeshima H, Sasaki A, Fukuda M Hashimoto T, Naka T, Ishizu K, Sekine S, Yoshikawa T, Hamada A, Yamamichi N, Fujishiro M and Ushijima T. Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation. **Gut**, 73: 255-267, 2024. (IF=23.0)
2. Irie T, Yamada H, Takeuchi C, Liu YY, Charvat H, Shimazu T, Ando T, Maekita T, Abe S, Takamaru H, Kodama M, Murakami K, Sugimoto K, Sakamoto K and Ushijima T. The methylation level of a single cancer risk marker gene reflects methylation burden in gastric mucosa, **Gastric Cancer**, 26: 667-676, 2023. (IF=6.0)
3. Ueda S, Yamashita S, Nakajima M, Kumamoto T, Ogawa C, Liu YY, Yamada H, Kubo E, Hattori N, Takeshima H, Wakabayashi M, Iida N, Shiraishi Y, Noguchi M, Sato Y and Ushijima T. A quantification method of somatic mutations in normal tissues and their accumulation in pediatric patients with chemotherapy. **Proc Natl Acad Sci USA**, 119: e2123241119, 2022. (IF=9.4)
4. Ushijima T, Clark SJ and Tan P. Mapping genomic and epigenomic evolution in cancer ecosystems. **Science**, 373: 1474-1479, 2021. (IF=44.7)
5. Takeshima H, Niwa T, Yamashita S, Takamura-Enya T, Iida N, Wakabayashi M, Nanjo S, Abe M, Sugiyama T, Kim YJ and Ushijima T. *TET* repression and increased DNMT activity synergistically induce aberrant DNA methylation. **J Clin Invest**, 130: 5370-5379, 2020. (IF=13.3)

Main Scientific Publications

6. Maeda M, Takeshima H, Iida N, Hattori N, Yamashita S, Moro H, Yasukawa Y, Nishiyama K, Hashimoto T, Sekine S, Ishii G, Ochiai A, Fukagawa T, Katai H, Sakai Y and Ushijima T. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3. **Gut**, 69: 243-251, 2020. (IF=23.0)
7. Yamashita S, Kishino T, Takahashi T, Shimazu T, Charvat H, Kakugawa Y, Nakajima T, Lee YC, Iida N, Maeda M, Hattori N, Takeshima H, Nagano R, Oda I, Tsugane S, Wu MS and Ushijima T. Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues. **Proc Natl Acad Sci USA**, 115: 1328-1333, 2018. (IF=9.4)
8. Maeda M, Nakajima T, Oda I, Shimazu T, Yamamichi N, Maekita T, Asada K, Yokoi C, Ando T, Yoshida T, Nanjo S, Fujishiro M, Gotoda T, Ichinose M and Ushijima T. High impact of methylation accumulation on metachronous gastric cancer: 5-year follow up of a multicentre prospective cohort study. **Gut**, 66: 1721-1723, 2017. (IF=23.0)
9. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M and Ushijima T. Inflammatory processes triggered by *Helicobacter pylori* infection cause aberrant DNA methylation in gastric epithelial cells. **Cancer Res**, 70: 1430-1440, 2010. (IF=12.5)
10. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M and Ushijima T. High levels of aberrant DNA methylation in *Helicobacter pylori*-infected gastric mucosae and its possible association with gastric cancer risk. **Clin Cancer Res**, 12: 989-995, 2006. (IF=10.0)